Dr. Daniele on Impact of Regorafenib in HCC

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the potential impact of regorafenib (Stivarga) for the treatment of patients with hepatocellular carcinoma (HCC).

Regorafenib will change the treatment landscape because it significantly increases survival in patients, Daniele explains.

However, it is important to note the therapeutic sequence of systemic therapy because, overall, the combination of sorafenib (Nexavar) and regorafenib in sequence is associated with a median overall survival of 26 months.

<<<

View more from the 2016 World Congress on GI Cancer